At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
In Brief
A Phase 2 clinical trial evaluating Berzosertib, Computed Tomography Assisted Biopsy, and 3 other interventions for Clinical Stage III Gastric Cancer AJCC v8 and 7 related conditions. Active but no longer recruiting, targeting 17 participants across 31 sites.
Detailed Summary
This phase II trial studies the how well berzosertib and irinotecan work in treating patients with gastric or gastroesophageal junction cancer that is growing, spreading or getting worse (progressive), has spread to other places in the body (metastatic), or cannot be removed by surgery (unresectable). Berzosertib may stop the growth of tumor cells by blocking some of the enzymes needed for growth. Chemotherapy drugs, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving berzosertib and irinotecan may work better than irinotecan alone in treating patients with gastric and gastroesophageal junction cancer.
Study Details
Timeline
Interventions
Given IV
Undergo CT assisted biopsy
Undergo endoscopic biopsy
Given IV
Undergo MRI